Akeso (AKESF) said its experimental lung cancer treatment ivonescimab improved overall survival compared with a widely used ...

Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous ...

In the retrospective validation cohort of 205 patients with PD-L1-High mNSCLC without actionable mutations, patients classified as Onclara IO High had a median overall survival of 484 days, compared ...

Dual PD-L1 and VEGF-A blockade with pumitamig plus chemotherapy yielded a 70% overall response rate and 100% disease control in evaluable first-line advanced NSCLC without actionable alterations.

Drugmakers including BioNTech, Merck & Co. and Pfizer are all testing their investigational PD-1/VEGF bispecifics against ...

Summit Therapeutics Inc. declined Monday after doctors questioned whether positive survival data from a Chinese trial of the company’s lung cancer drug ivonescimab would translate to the generally ...

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ...

Background: As the use of immune checkpoint inhibitors in postoperative adjuvant chemotherapy for patients with programmed death-ligand 1 (PD-L1)-expressing lung cancer has been increasing, it is ...

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various ...

A large clinical trial in China (HARMONi-6) found that a new immunotherapy drug, ivonescimab, may help patients with advanced ...

Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the ...